Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. (Q51415177)

5 April 2018

title

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. (English)

1 reference

5 April 2018

1 reference

1 reference

Vollenweider FX

1

1 reference

5 April 2018

Vontobel P

2

1 reference

5 April 2018

Oye I

3

1 reference

5 April 2018

Hell D

4

1 reference

5 April 2018

Leenders KL

5

1 reference

5 April 2018

publication date

1 January 2000

1 reference

5 April 2018

Journal of Psychiatric Research

published in

1 reference

5 April 2018

volume

34

1 reference

5 April 2018

page(s)

35-43

1 reference

5 April 2018

issue

1

1 reference

5 April 2018

Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Differential control by N-methyl-D-aspartate and kainate of striatal dopamine release in vivo: a trans-striatal dialysis study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

The standardized psychometric assessment of altered states of consciousness (ASCs) in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Hypofrontality revisited: a high resolution single photon emission computed tomography study in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

(3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Comparison of methods for analysis of clinical [11C]raclopride studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Simplified reference tissue model for PET receptor studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Alterations in striatal dopamine overflow during rotational behavior induced by amphetamine, phencyclidine, and MK-801.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Distribution of N-methyl-D-aspartate-sensitive L-[3H]glutamate-binding sites in rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: A resting and activation SPECT study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

The role of N-methyl-D-aspartate receptors in the regulation of physiologically released dopamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

Effects of phencyclidine, MK-801 and 1,3-di(2-tolyl)guanidine on non-dopaminergic midbrain neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2899%2900031-X

10.1016/S0022-3956(99)00031-X

7 January 2021

Identifiers

DOI

1 reference

5 April 2018

PubMed ID

10696831

1 reference

5 April 2018